Quark Venture
VC Fund
Vancouver, Canada
Quark Venture is a VC fund in Vancouver focused on Biotechnology and Health Care. Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 34%
Last updated:
For AI agents: llms.txt
Industries Quark Venture invests in
Stages Quark Venture invests in
Countries Quark Venture invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Biotechnology 16 (46%)
- Health Care 12 (34%)
- Therapeutics 9 (26%)
- Medical 7 (20%)
- Pharmaceutical 7 (20%)
Stage
- Series B 12 (34%)
- Series C 5 (14%)
- Funding Round 5 (14%)
- Seed 2 (6%)
- Series A 2 (6%)
Country
- United States 13 (37%)
- Canada 6 (17%)
- Israel 4 (11%)
- France 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Karimah Es Sabar
Chief Executive Officer & Partner
|
Chief Executive Officer & Partner | Total investments: 8 | Find email | |
Neena Kadaba
Director, Science
|
Director, Science | Total investments: 1 | Find email | |
Zafrira Avnur
Chief Scientific Officer
|
Chief Scientific Officer | Total investments: 3 | Find email | |
|
Jesson Chen
Co-Founder, Chairman & Partner
|
Co-Founder, Chairman & Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alpha-9 Oncology
|
Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $75M / Series B / Dec 14, 2022 | |
V-Wave
|
V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $98M / Series C / Dec 16, 2021 | |
Lyndra Therapeutics
|
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $60.5M / Series C / Jun 24, 2021 | |
Volastra Therapeutics
|
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability | $32M / Seed / Apr 06, 2021 | |
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
|
V-Wave
|
V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $28M / Series C / Sep 22, 2020 | |
EnClear Therapies
|
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | $10M / Series A / Feb 19, 2020 | |
|
Volastra Therapeutics
|
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability | $12M / Seed / Feb 11, 2020 | |
Eyevensys
|
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures. | $30M / Series B / Jan 08, 2020 | |
| See all 35 investments → | |||
Co-Investors
GF Securities
13 deals together
Pontifax
10 deals together
Global health sciences venture fund
8 deals together
Polaris Partners
5 deals together
Triventures
4 deals together
Aperture Venture Partners
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Quark Venture invest in?
Quark Venture invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Quark Venture?
Public channels for Quark Venture include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Quark Venture?
The team at Quark Venture includes Karimah Es Sabar (Chief Executive Officer & Partner), Neena Kadaba (Director, Science) and Zafrira Avnur (Chief Scientific Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
